Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million infections and 1 million deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here, we examine the properties of highly potent human monoclonal antibodies (hu-mAb...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäfer, Alexandra, Muecksch, Frauke, Lorenzi, Julio C.C., Leist, Sarah R., Cipolla, Melissa, Bournazos, Stylianos, Schmidt, Fabian, Maison, Rachel M., Gazumyan, Anna, Martinez, David R., Baric, Ralph S., Robbiani, Davide F., Hatziioannou, Theodora, Ravetch, Jeffrey V., Bieniasz, Paul D., Bowen, Richard A., Nussenzweig, Michel C., Sheahan, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673958/
https://www.ncbi.nlm.nih.gov/pubmed/33211088
http://dx.doi.org/10.1084/jem.20201993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673958/
https://www.ncbi.nlm.nih.gov/pubmed/33211088
http://dx.doi.org/10.1084/jem.20201993

Ejemplares similares